These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 33051619)

  • 1. Sarcomatoid renal cell carcinoma: biology, natural history and management.
    Blum KA; Gupta S; Tickoo SK; Chan TA; Russo P; Motzer RJ; Karam JA; Hakimi AA
    Nat Rev Urol; 2020 Dec; 17(12):659-678. PubMed ID: 33051619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
    Chandrasekaran D; Sundaram S; N K; R P
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2951-2957. PubMed ID: 31653140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
    Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
    Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.
    Lebacle C; Pooli A; Bessede T; Irani J; Pantuck AJ; Drakaki A
    World J Urol; 2019 Jan; 37(1):115-123. PubMed ID: 29858701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma.
    Shuch B; Bratslavsky G; Shih J; Vourganti S; Finley D; Castor B; Treat E; Linehan WM; Pantuck AJ; Said JW; Belldegrun AS
    BJU Int; 2012 Jun; 109(11):1600-6. PubMed ID: 22221668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathological features and prognosis of renal cell carcinoma with sarcomatoid differentiation].
    Jiang Y; Su G; Yu W; Li J; Lu Q; Li Y; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):823-6. PubMed ID: 26887511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
    Keskin SK; Msaouel P; Hess KR; Yu KJ; Matin SF; Sircar K; Tamboli P; Jonasch E; Wood CG; Karam JA; Tannir NM
    J Urol; 2017 Sep; 198(3):530-537. PubMed ID: 28411072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcomatoid renal cell carcinoma: Biology and treatment advances.
    Mouallem NE; Smith SC; Paul AK
    Urol Oncol; 2018 Jun; 36(6):265-271. PubMed ID: 29306556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
    McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
    Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications.
    Miolo G; Ash A; Buonadonna A; Lo Re G; Torrisi E; Cervo S; Santeufemia DA; Tuzi A; Canzonieri V
    Cancer Biol Ther; 2014; 15(11):1439-43. PubMed ID: 25482943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases.
    Abel EJ; Carrasco A; Culp SH; Matin SF; Tamboli P; Tannir NM; Wood CG
    BJU Int; 2012 Dec; 110(11):1742-6. PubMed ID: 22503066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
    Li CJ; Lin LT; Hou MF; Chu PY
    Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
    Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
    Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
    Chahoud J; Msaouel P; Ross JA; McCormick BZ; Bathala TK; Gao J; Horn R; Xiao L; Sircar K; Campbell MT; Shah AY; Goswami S; Zurita AJ; Jonasch E; Matin SF; Wood CG; Karam JA; Sharma P; Tannir NM
    Urol Oncol; 2021 Feb; 39(2):134.e9-134.e16. PubMed ID: 33187886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromophobe renal cell carcinoma with sarcomatoid change. A case report.
    Nagashima Y; Okudela K; Osawa A; Nakamura N; Kawasaki C; Moriyama M; Nakamura N; Nakatani Y; Kitamura H; Aoki I
    Pathol Res Pract; 2000; 196(9):647-51; discussion 652. PubMed ID: 10997740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects.
    Kuroda N; Toi M; Hiroi M; Enzan H
    Histol Histopathol; 2003 Apr; 18(2):551-5. PubMed ID: 12647806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.